18.20
+0.28%
Close of 9 Nov 2026, in TWD
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About TFBS Bioscience
Its shares trade on Taipei Exchange under the ticker 6939.TWO. It has been listed since 15 May 2023. In the fiscal year to 31 December 2025, it reported revenue of TWD 193.1m and a net loss of TWD 74.5m. At that date it held total assets of TWD 1.46bn and shareholders' equity of TWD 1.16bn.
TFBS Bioscience Inc is a Taiwan-based company mainly engaged in the provision of biotechnology drug testing services and viral vector contract manufacturing. The company is headquartered in Taipei, New Taipei. The company went IPO on 2023-05-15. The firm's main products include biosafety analysis, core laboratory services, research and development, animal testing, good manufacturing practice grade manufacturing and others. The firm mainly provides services in Taiwan.
Figures and description from our data supplier, not checked against the company's own report.
Company facts
- Sector
- Health Care
- Industry
- Life Sciences Tools & Services
- Listed since
- 15 May 2023
- Website
- tfbsbio.com ↗
Leadership
Pay as last reported
- Mr. Tatung YuanChairman of the Board, Chief Executive Officer, since 2016
- Mr. Wilson LiaoChief Financial Officer, since 2023
- Ms. Gloria HuangChief Operating Officer, Corporate Governance Officer
- Manxiu JiangChief Technology Officer
- Mr. Peiyu WuChief Research & Development Officer-R&D Division
- Mr. Chih-Jung ChangDirector
- Ms. Amy HuangDirector
- Mr. Lixin HuangDirector
- Mr. Qianyue HuangDirector
- Mr. Hsin Yu LeeIndependent Director
- Mr. Heng-Chih LinIndependent Director
- Mr. Yong-Sheng LiuIndependent Director
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 0
- Environment
- 0
- Social
- 0
- Governance
- 0
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- TFBS Bioscience Inc offers biosafety analysis services in Taiwan with strong local market presence.
- The company provides core laboratory services and animal testing for biotechnology drug development.
- TFBS Bioscience Inc has good manufacturing practice grade manufacturing capabilities in Taipei.
Weaknesses
- The company's services are primarily limited to Taiwan, restricting international expansion.
- TFBS Bioscience Inc lacks a global manufacturing footprint beyond Taipei.
- The firm's reliance on Taiwan's biotechnology sector may pose regional dependency risks.
Opportunities
- Growing demand for viral vector contract manufacturing in the Life Sciences Tools & Services sector.
- Expansion of biosafety analysis services to meet increasing regulatory requirements in Taiwan.
- Potential for R&D collaboration with international biotech firms in the Health Care sector.
Threats
- Regulatory changes in Taiwan's Health Care sector could impact service delivery.
- Competition from international biotech firms entering the Taiwan market.
- Economic downturns in Taiwan may reduce demand for biotechnology services.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.